Plain-English translation of NCT06663059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new immunotherapy drug called Adebrelimab, combined with standard chemotherapy drugs, to treat advanced esophageal cancer before surgery. Researchers want to know whether two treatment cycles work as well as four cycles—or whether giving more treatment helps patients have better outcomes after their surgery.
Doctors currently use chemotherapy before surgery for advanced esophageal cancer, but results are not always as good as hoped. This medication may help the immune system fight cancer more effectively, and researchers want to find the best number of treatment cycles to give patients the best chance of success with fewer side effects.
You likely qualify if…
You likely don't qualify if…
After screening tests and consent, you will be randomly assigned to receive either two or four cycles of the medication combined with chemotherapy—with each cycle lasting about 3 weeks. You will have regular visits for infusions, blood tests, and scans to monitor how well the treatment is working. Once your treatment is complete, you will undergo surgery to remove the cancer, followed by long-term follow-up visits to check your health and watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China